China Regulatory Express: New Cell Therapy, Gene Editing Guidelines Proposed
Two-Track Pathway Remains
Given the high number of such trials in the country, China’s National Medical Products Administration has released separate guidelines for industry on the development of gene and cell therapies and gene editing clinical research.
